Inrebic
Chemical Name | fedratinib |
Dosage Form | Capsule (oral; 100 mg) |
Drug Class | Kinase inhibitors |
System | Blood |
Company | Impact |
Approval Year | 2019 |
Indication
- Inrebic is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF).